TY - JOUR
T1 - Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer
AU - Miyamoto, Yuji
AU - Baba, Yoshifumi
AU - Sakamoto, Yasuo
AU - Ohuchi, Mayuko
AU - Tokunaga, Ryuma
AU - Kurashige, Junji
AU - Hiyoshi, Yukiharu
AU - Iwagami, Shiro
AU - Yoshida, Naoya
AU - Watanabe, Masayuki
AU - Baba, Hideo
N1 - Publisher Copyright:
© 2015 Miyamoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/6/12
Y1 - 2015/6/12
N2 - Background: Skeletal muscle depletion (sarcopenia) is closely associated with limited physical ability and high mortality. This study evaluated the prognostic significance of skeletal muscle status before and after chemotherapy in patients with unresectable colorectal cancer (CRC). Methods: We conducted a retrospective analysis of 215 consecutive patients with unresectable CRC who underwent systemic chemotherapy. Skeletal muscle cross-sectional area was measured by computed tomography. We evaluated the prognostic value of skeletal muscle mass before chemotherapy and the rate of skeletal muscle change in cross-sectional area after chemotherapy. Results: One-hundred-eighty-two patients met our inclusion criteria. There were no significant differences in progression-free survival (PFS) or overall survival (OS) associated with skeletal muscle mass before chemotherapy. However, 22 patients with skeletal muscle loss (>5%) after chemotherapy showed significantly shorter PFS and OS compared with those without skeletal muscle loss (PFS, log-rank p = 0.029; OS, log-rank p = 0.009). Multivariate Cox regression analysis revealed that skeletal muscle loss after chemotherapy (hazard ratio, 2.079; 95% confidence interval, 1.194-3.619; p = 0.010) was independently associated with OS. Conclusions: Skeletal muscle loss after chemotherapy was an independent, negative prognostic factor in unresectable CRC.
AB - Background: Skeletal muscle depletion (sarcopenia) is closely associated with limited physical ability and high mortality. This study evaluated the prognostic significance of skeletal muscle status before and after chemotherapy in patients with unresectable colorectal cancer (CRC). Methods: We conducted a retrospective analysis of 215 consecutive patients with unresectable CRC who underwent systemic chemotherapy. Skeletal muscle cross-sectional area was measured by computed tomography. We evaluated the prognostic value of skeletal muscle mass before chemotherapy and the rate of skeletal muscle change in cross-sectional area after chemotherapy. Results: One-hundred-eighty-two patients met our inclusion criteria. There were no significant differences in progression-free survival (PFS) or overall survival (OS) associated with skeletal muscle mass before chemotherapy. However, 22 patients with skeletal muscle loss (>5%) after chemotherapy showed significantly shorter PFS and OS compared with those without skeletal muscle loss (PFS, log-rank p = 0.029; OS, log-rank p = 0.009). Multivariate Cox regression analysis revealed that skeletal muscle loss after chemotherapy (hazard ratio, 2.079; 95% confidence interval, 1.194-3.619; p = 0.010) was independently associated with OS. Conclusions: Skeletal muscle loss after chemotherapy was an independent, negative prognostic factor in unresectable CRC.
UR - http://www.scopus.com/inward/record.url?scp=84935442204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84935442204&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0129742
DO - 10.1371/journal.pone.0129742
M3 - Article
AN - SCOPUS:84935442204
SN - 1932-6203
VL - 10
JO - PLoS One
JF - PLoS One
IS - 6
M1 - e0129742
ER -
